Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial

OBJECTIVES: Varenicline was approved by the FDA in 2006. In 2009, based largely on case reports, the FDA issued a warning of possible adverse neuropsychiatric effects including depression and suicidal thoughts and behavior for varenicline and bupropion. Prospective trials of varenicline have not rep...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Pachas, Gladys N., Cather, Corinne, Pratt, Sarah A., Hoeppner, Bettina, Nino, Johanna, Carlini, Sara V., Achtyes, Eric D., Lando, Harry, Mueser, Kim T., Rigotti, Nancy A., Goff, Donald C., Evins, A. Eden
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3414422/
https://ncbi.nlm.nih.gov/pubmed/22888309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15504263.2012.663675
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi